I am starting this thread as I did a little research after someone posted a question on IrhSOD and a quite promising study.
the study:
http://www.europeanurology.com/article/S0302-2838%2805%2900256-3/fulltextConclusion:
With the premise that conservative therapies for Peyronie's Disease generally are symptom-directed, i.e. analgesic and preventive against disease progression, and correction of deviation stays a surgical domain, liposomally encapsulated recombinant human SOD shows good efficacy when administered in patients with painful Peyronie's Disease lesions. Compared to placebo a statistical significant reduction of pain symptoms was observed resulting in an overall efficacy of >80% after 8 weeks of therapy. The expected rate of spontaneous disease progression was obviously reduced, as was morbidity and the need for future surgery, resulting in a high rate of patients satisfaction. There are no data on lrhSOD therapy exceeding 2 months, but a longer treatment time could possibly effect a more pronounced response on penile plaques and curvature. Future studies with a larger population may be difficult to perform, due to the relative infrequency and variable presentation of Peyronie's Disease. However, they are necessary to clarify the questions of optimal lrhSOD concentration and treatment duration.
After george's comment :
The major problem with lrhSOD is that it apparently was formulated specifically for this study and is apparently not in commercial production. Certainly Levine speaks favorably of this treatment even seeming to wish that it was actually available to prescribe, which it pretty obviously isn't. He also notes that the technique itself holds promise, in that other compounds might work in similar fashion, some perhaps even more effectively. So it looks like they did this obviously successful study and there has been no follow up from the pharmaceutical industry to make the product available. Obviously someone must hold the patent rights to it. In the mean time five years have gone by. It could well end up just being another missed opportunity. Fortunately, though, we DO have the oral treatments. - George
i dug a little into it..
Here is what I found:
Apparently they are using an ointment (gel) based on an experimental drug called
LipoxysanThe company that created this drug wants 2 clinical studies, one for treatment of Peyronies Disease, a second one for burns:
To proof the potency of this lipsomal fomulation, two clinical trials will be performed. First, a clinical study for the treatment of Peyronie Disease (IPP) will be carried out. The efficacy of Lipoxysan against the inflammatory response will be evaluated. In the second approach, studies with Lipoxysan to reduce post-burn edema and improvement in wound healing will be performed. The treatment will be evaluated in first and second degree burns.
Now here is the interesting part. Allthough Lipoxysan is not sold in pharmacies, it is possible to get it if you are a lab.
You and me probably will not have the possibility to use it as is, but I think if you have a compliant pharmacist he could mix you a gel (or another topical mixture based on the product)
Here is what it says in the study:
A gel containing 2 mg liposomal recombinant human Cu-Zn SOD/g (Lipoxysan®) was manufactured under GMP conditions (Polymun Scientific, Vienna, Austria). The study drug and placebo were aseptically filled into 20 ml syringes which allowed controlled dosing of the gel.
Here is the link to the company in Austria:
http://www.polymun.com/(its a frame page, so click in the right column on: Superoxide Dismutase)
there you can see the pricing is 300€ (about 420$) for 20mg) (2mg seem to be needed per application)
There is a pdf datasheet also
Of course it cannot be used as is. A pharmacist would have to make a mixture, but it seems that the product as it is, is not very stable and has to be used in a sterile environment.
-------------
additional info:
In October 2010, Polymun has concluded an exclusive agreement with Apeiron Biologics AG for development and marketing of SOD.
http://www.apeiron-biologics.com/The only reference I found on their homepage:
# APN201 (rhSOD):
# Development stage: Phase II
# Development of a liposomal formulation of recombinant human Superoxide Dismutase (rhSOD) for therapy inflammatory skin conditions.
The human antioxidant enyzme Superoxide Dismutase is essential for protecting our cells from damage by reactive oxygen species. In October 2010, Apeiron has licensed recombinant human SOD from Polymun Scientific. A proprietary liposomal formulation of this enzyme that is well suited for topical application was already tested in several clinical trials and has shown therapeutic effects in a variety of inflammatory skin conditions. It is now intended to clinically develop liposomal SOD against skin damage as consequence of cancer therapies such as radiation therapy.
-------------
I will try in the next weeks to contact them, and see if they have allready a finished product or some topical gel.
Luc
Author
Topic: Some additional information on lrhSOD and Peyronies Disease (Read 7319 times)
May 20, 2017, 09:24:05 AM